title: In vivo 31P magnetic resonance spectroscopy and 1H magnetic resonance imaging of human bladder carcinoma on nude mice: effects of tumour growth and treatment with cis-dichloro-diamine platinum.
abstract: In vivo 31P NMR spectroscopy and 1H NMR imaging were used to examine the bladder T24B carcinoma in nude mice during untreated growth and in response to chemotherapy by Cis-dichloro-diammine-platinum (CDDP) at a dose of 8 mg/kg i.p. Untreated growth was associated with an increase of inorganic phosphate and phosphomonoesters and a decrease of phosphocreatine. Fast growing tumours and early stage of regrowth after treatment presented a higher phosphocreatine/beta NTP ratio. Following CDDP treatment, 31P metabolite ratios and pH were significantly altered compared with age-matched controls, as early as 6 hours after treatment. Although necrotic area was clearly visible in MRI, no treatment effect could be detected on the images of treated tumours.
authors.affiliation: Danish Research Center of Magnetic Resonance, Hvidovre Hospital, Copenhagen.
authors.forename: J D
authors.initials: JD
authors.lastname: De Certaines
authors.forename: J
authors.initials: J
authors.lastname: Albrectsen
authors.forename: V A
authors.initials: VA
authors.lastname: Larsen
authors.forename: X
authors.initials: X
authors.lastname: Xie
authors.forename: J
authors.initials: J
authors.lastname: Rygaard
authors.forename: O
authors.initials: O
authors.lastname: Henriksen
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010761:Phosphorus Radioisotopes; D014183:Transplantation, Heterologous; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology*
chemical_list: D009944:Organoplatinum Compounds; D010761:Phosphorus Radioisotopes; C055423:didimethylsulfoxide dichloroplatinum(II)